Plant Name: Eremophila oppositifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.363E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.996E-10 | 1.450E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.613E-09 | 3.025E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.667E-09 | 3.025E-06 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.899E-09 | 4.508E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.926E-09 | 1.023E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.197E-08 | 1.241E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 1.152E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.235E-07 | 5.251E-04 | CYP2D6, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.059E-06 | 1.401E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.410E-06 | 1.500E-03 | DRD1, DRD2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 5.223E-06 | 2.774E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1, DRD2, LMNA |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 6.743E-06 | 3.415E-03 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 1.083E-05 | 5.127E-03 | DRD1, DRD2 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 1.323E-05 | 6.132E-03 | DRD1, DRD2 |
| BP | GO:0051179; localization | GO:0015872; dopamine transport | 1.588E-05 | 6.779E-03 | DRD1, SLC22A2 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0004952; dopamine neurotransmitter receptor activity | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.750E-17 | 1.470E-12 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.048E-10 | 3.250E-09 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.439E-10 | 1.153E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.373E-08 | 3.486E-07 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.409E-08 | 4.192E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.868E-06 | 2.398E-05 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.994E-05 | 1.030E-04 | CYP2C9; CYP2D6; CYP2C19 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.613E-04 | 1.157E-03 | DRD1; DRD2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.187E-04 | 1.442E-03 | CYP2C9; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.664E-04 | 1.420E-03 | CYP1A2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.418E-04 | 2.610E-03 | DRD1; DRD2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.276E-03 | 5.426E-03 | CYP2C9; CYP1A2; CYP2C19; CYP3A4 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.796E-03 | 5.061E-03 | DRD1; DRD2 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 2.170E-03 | 5.426E-03 | DRD1; DRD2 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 3.419E-03 | 7.067E-03 | DRD1; DRD2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.206E-03 | 8.149E-03 | DRD1; DRD2 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.993E-03 | 1.457E-02 | DRD1; DRD2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.983E-02 | 3.414E-02 | CYP1A2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.277E-02 | 3.715E-02 | CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.498E-03 | 5.531E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| NA: NA | Itching | NA | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2 |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; DRD2; DRD2; DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; CYP2C9 |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; CYP3A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2 |
| NA: NA | False perceptions | NA | DRD2 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2 |
| NA: NA | Vomiting | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1 |
| NA: NA | Hyperaemia | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; DRD2 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |